

SUPPLEMENTAL MATERIAL

Supplemental Table 1. Sensitivity analysis of odds of heart failure medication prescription during clinic visits for patients with heart failure and a left ventricular ejection fraction $\leq 35\%$.

	Pre-Covid vs. Covid Era OR (95%CI)	Covid In-Person vs. Covid Video	Covid In-Person vs. Covid Telephone
Unadjusted logistic model			
<i>Any GDMT</i>	0.75 (0.68-0.84)	0.84 (0.66-1.07)	0.52 (0.42-0.65)
<i>Beta-Blocker</i>	0.77 (0.68-0.88)	0.81 (0.60-1.09)	0.60 (0.46-0.77)
<i>ACE/ARB/ARNI</i>	0.60 (0.49-0.74)	0.62 (0.35-1.08)	0.65 (0.43-1.00)
<i>MRA</i>	0.82 (0.66-1.01)	0.71 (0.42-1.18)	0.43 (0.27-0.70)
<i>Hydralazine</i>	0.78 (0.49-1.24)	0.24 (0.03-1.74)	1.17 (0.54-2.54)
<i>Nitrates</i>	0.98 (0.61-1.56)	0.40 (0.10-1.69)	0.78 (0.34-1.78)
<i>Digoxin</i>	0.78 (0.51-1.20)	0.88 (0.34-2.26)	0.29 (0.09-0.94)
<i>Loop Diuretics</i>	0.80 (0.70-0.93)	0.71 (0.51-1.00)	0.47 (0.34-0.64)
Logistic + multivariable adjustment			
<i>Any GDMT</i>	0.81 (0.72-0.90)	0.91 (0.70-1.19)	0.63 (0.50-0.80)
<i>Beta-Blocker</i>	0.83 (0.73-0.95)	0.86 (0.62-1.19)	0.70 (0.53-0.93)
<i>ACE/ARB/ARNI</i>	0.58 (0.47-0.72)	0.65 (0.36-1.19)	0.65 (0.41-1.04)
<i>MRA</i>	0.89 (0.71-1.11)	0.78 (0.45-1.36)	0.60 (0.36-1.02)
<i>Hydralazine</i>	0.86 (0.53-1.40)	0.42 (0.05-3.40)	1.72 (0.71-4.16)
<i>Nitrates</i>	0.97 (0.60-1.58)	0.53 (0.12-2.39)	0.89 (0.36-2.24)
<i>Digoxin</i>	0.91 (0.58-1.41)	0.81 (0.29-2.30)	0.32 (0.09-1.11)
<i>Loop Diuretics</i>	0.88 (0.76-1.02)	0.84 (0.58-1.22)	0.56 (0.40-0.78)
Logistic + multivariable adjustment + clustering by patient			
<i>Any GDMT</i>	0.80 (0.72-0.90)	0.88 (0.67-1.15)	0.62 (0.49-0.79)
<i>Beta-Blocker</i>	0.83 (0.73-0.94)	0.81 (0.59-1.12)	0.68 (0.51-0.90)
<i>ACE/ARB/ARNI</i>	0.58 (0.47-0.72)	0.69 (0.38-1.25)	0.67 (0.42-1.06)
<i>MRA</i>	0.88 (0.71-1.10)	0.74 (0.42-1.29)	0.58 (0.34-0.98)
<i>Hydralazine</i>	0.86 (0.53-1.39)	0.33 (0.04-2.69)	1.63 (0.67-3.95)
<i>Nitrates</i>	0.98 (0.61-1.59)	0.51 (0.11-2.30)	0.85 (0.34-2.14)
<i>Digoxin</i>	0.91 (0.59-1.42)	0.90 (0.32-2.58)	0.33 (0.09-1.14)
<i>Loop Diuretics</i>	0.88 (0.76-1.02)	0.83 (0.57-1.21)	0.56 (0.40-0.78)
Logistic + multivariable adjustment + clustering by patient + propensity weighting			
<i>Any GDMT</i>	-	0.90 (0.77-1.05)	0.55 (0.48-0.64)
<i>Beta-Blocker</i>	-	0.82 (0.68-0.99)	0.61 (0.52-0.72)
<i>ACE/ARB/ARNI</i>	-	0.82 (0.59-1.15)	0.54 (0.40-0.72)
<i>MRA</i>	-	0.69 (0.50-0.96)	0.48 (0.35-0.66)
<i>Hydralazine</i>	-	0.18 (0.04-0.90)	1.52 (0.89-2.61)
<i>Nitrates</i>	-	0.29 (0.10-0.82)	0.65 (0.36-1.19)
<i>Digoxin</i>	-	0.91 (0.48-1.72)	0.28 (0.13-0.58)
<i>Loop Diuretics</i>	-	0.67 (0.53-0.85)	0.45 (0.37-0.55)

	Pre-Covid vs. Covid Era OR (95% CI)	Covid In-Person vs. Covid Video	Covid In-Person vs. Covid Telephone
Only patients seen in both pre-Covid and Covid eras			
<i>Any GDMT</i>	0.67 (0.58-0.77)	0.75 (0.60-0.94)	0.58 (0.48-0.70)
<i>Beta-Blocker</i>	0.72 (0.61-0.85)	0.78 (0.60-1.02)	0.72 (0.58-0.89)
<i>ACE/ARB/ARNI</i>	0.47 (0.36-0.62)	0.59 (0.35-0.97)	0.25 (0.15-0.42)
<i>MRA</i>	0.79 (0.59-1.04)	0.47 (0.28-0.80)	0.38 (0.23-0.60)
<i>Hydralazine</i>	0.97 (0.55-1.72)	0.24 (0.04-1.41)	2.92 (1.54-5.53)
<i>Nitrates</i>	1.01 (0.56-1.81)	0.33 (0.09-1.26)	0.82 (0.41-1.64)
<i>Digoxin</i>	0.93 (0.55-1.58)	0.98 (0.46-2.08)	0.23 (0.09-0.58)
<i>Loop Diuretics</i>	0.79 (0.65-0.94)	0.90 (0.68-1.19)	0.40 (0.30-0.52)
Only patients seen in non-Covid-19-surge months			
<i>Any GDMT</i>	0.83 (0.73-0.94)	0.90 (0.74-1.08)	0.65 (0.55-0.77)
<i>Beta-Blocker</i>	0.87 (0.75-1.02)	0.68 (0.54-0.86)	0.70 (0.57-0.85)
<i>ACE/ARB/ARNI</i>	0.61 (0.48-0.77)	1.04 (0.72-1.51)	0.62 (0.45-0.87)
<i>MRA</i>	0.91 (0.70-1.17)	1.01 (0.71-1.44)	0.42 (0.27-0.64)
<i>Hydralazine</i>	0.91 (0.52-1.57)	0.32 (0.06-1.70)	2.33 (1.22-4.44)
<i>Nitrates</i>	1.08 (0.61-1.91)	0.53 (0.18-1.58)	0.95 (0.47-1.89)
<i>Digoxin</i>	1.18 (0.69-2.01)	0.39 (0.14-1.10)	0.38 (0.18-0.83)
<i>Loop Diuretics</i>	0.89 (0.75-1.05)	0.84 (0.65-1.09)	0.49 (0.38-0.62)

GDMT includes evidence-based Beta Blocker, ACEi, ARB, ARNI, MRA, Hydralazine or Nitrates (if patient identified as black), or digoxin

Beta blocker = metoprolol, carvedilol, bisoprolol, or nebivolol

Nitrates = isosorbide dinitrate or isosorbide mononitrate

Multivariable adjustment adjusted for age, sex, race, insurance status, calendar date, visit length, and visit diagnoses (coronary artery disease, hypertension, atrial fibrillation/flutter, diabetes mellitus, valvular disease, and chronic kidney disease).

Propensity weighting was calculated based on propensity for being seen by remote visit according to above patient characteristics.

Non-Covid-19-surge months excluded outpatient visits during peak months of the Covid-19 pandemic in Los Angeles (June, December)

Abbreviations: GDMT = guideline directed medical therapy, ACEi = angiotensin converting enzyme inhibitor, ARB = angiotensin receptor blocker, MRA = mineralocorticoid receptor antagonist, Ref = reference